HUM Quantitative Stock Analysis

Humana (HUM) received a 70% rating from Validea's analysis using Meb Faber's Shareholder Yield Investor model, falling below the 80% threshold for 'some interest' in the strategy. While HUM passed criteria for valuation and quality/debt, it notably failed the critical 'NET PAYOUT YIELD' and 'SHAREHOLDER YIELD' tests, indicating it does not strongly align with the model's emphasis on companies returning cash to shareholders via dividends, buybacks, and debt paydown.

Analysis

Humana Inc. (HUM) receives a moderate 70% rating from Validea's implementation of Meb Faber's Shareholder Yield Investor model, a score that falls below the 80% threshold required to signal strategic interest. The analysis presents a notable contradiction: while HUM is identified as the highest-rated stock using this specific model, it fails the two most critical criteria, 'NET PAYOUT YIELD' and 'SHAREHOLDER YIELD'. This indicates that the company's current capital return program, combining dividends, buybacks, and debt paydown, is not sufficiently aggressive to meet the model's quantitative requirements. However, the report also highlights fundamental strengths, as HUM successfully passed tests related to its valuation, quality and debt profile, and relative strength. The overall mixed sentiment signal reflects this conflict, suggesting that while HUM possesses positive underlying financial characteristics, it does not currently align with the objectives of a pure shareholder yield-focused investment strategy.

Key Decisions for Investors

• Investors strictly following a shareholder yield strategy should view Humana with caution, as it fails the model's core tests for net payout and shareholder yield, indicating suboptimal capital returns relative to peers sought by this strategy.
• Given that the stock passes criteria for valuation and quality, investors with a focus on value or quality-at-a-reasonable-price (QARP) could consider this a signal for further due diligence, separating these factors from its capital return policy.
• Portfolio managers should monitor any future changes to Humana's capital allocation strategy, as a significant increase in buybacks or dividends could materially improve its score within this framework and alter its investment thesis for yield-oriented funds.